Literature DB >> 26201525

Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study.

Oidov Baatarkhuu1,2,3,4, Do Young Kim1,4, Pagbajabyn Nymadawa5, Seung Up Kim1,4, Kwang-Hyub Han1,5,4,6, Jazag Amarsanaa3, Dagvasumberel Gonchigsuren7, Ravjir Sanduijav8, Zundui Lkhagvasuren9, Naran Khorolsuren2, Ravjir Oyungerel2, Sang Hoon Ahn10,11,12.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) is the most common cancer in Mongolia. We aimed to investigate the clinical features, therapeutic modalities, overall survival and prognostic factors for Mongolian patients with HCC.
METHOD: One hundred ninety-five patients with HCC were consecutively enroled in our study.
RESULTS: The mean age was 61.7 years. The most common etiology for HCC was HCV infection (n = 89, 45.6%), followed by HBV infection (n = 67, 34.4%). The mean tumor diameter was 6.0 ± 2.6 cm. Only 29 (14.9%) patients had a single lesion, while 39 (20.2%) had >3 lesions. Extrahepatic metastasis to lung (n = 23), bone (n = 10) and lymph node (n = 3) were detected in 36 (18.5%) patients. Most patients had advanced HCC-88 (45.1%) in stage III and 57 (29.2%) in stage IV. Surgical resection was performed in 27 (13.8%) patients, RFA in 23 (11.8%) and TACE in 107 (54.9%). When all the patients were categorized as 'treated' (n = 156) and 'not treated' (n = 39), the 3-year survival was significantly lower in the 'not treated' group than in the 'treated' group (11 vs. 0%, P < 0.001). Tumor diameter (<3 cm vs. ≥3 cm), extrahepatic metastasis, TNM stage (I/II vs. III/IV) and treatment (or supportive care) were selected as independent predictors for survival.
CONCLUSIONS: High proportion of patients with HCC in Mongolia is diagnosed at an advanced stage and survival of these patients is lower compared to other countries. A surveillance system and referral policy for high-risk groups should be urgently established and implemented in Mongolia.

Entities:  

Keywords:  Hepatocellular carcinoma; Mongolia; Survival

Year:  2011        PMID: 26201525     DOI: 10.1007/s12072-011-9325-4

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  27 in total

1.  Prevalence and molecular epidemiology of GB virus C/hepatitis G virus infection in Mongolia.

Authors:  Y Kondo; M Mizokami; T Nakano; T Kato; R Ueda; M Mukaide; K Hikiji; T Ishida; D Dorjsuren; B Dashnyam; T Oyunsuren
Journal:  J Med Virol       Date:  1997-06       Impact factor: 2.327

2.  High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia.

Authors:  B Tsatsralt-Od; M Takahashi; T Nishizawa; J Inoue; D Ulaankhuu; H Okamoto
Journal:  Arch Virol       Date:  2005-07-14       Impact factor: 2.574

3.  Treatment of early hepatocellular carcinoma: Towards personalized therapy.

Authors:  Silvia Tremosini; María Reig; Carlos Rodríguez de Lope; Alejandro Forner; Jordi Bruix
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

4.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).

Authors:  Kyu Sik Jung; Seung Up Kim; Sang Hoon Ahn; Young Nyun Park; Do Young Kim; Jun Yong Park; Chae Yoon Chon; Eun Hee Choi; Kwang-Hyub Han
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

5.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

6.  The global health burden of infection-associated cancers in the year 2002.

Authors:  Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

7.  Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients.

Authors:  S Markovic; E Gadzijev; B Stabuc; L S Croce; F Masutti; M Surlan; P Berden; E Brencic; A Visnar-Perovic; F Sasso; V Ferlan-Marolt; F P Mucelli; R Cesar; M Sponza; C Tiribelli
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

8.  High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia.

Authors:  Masaharu Takahashi; Tsutomu Nishizawa; Yuhko Gotanda; Fumio Tsuda; Fumio Komatsu; Terue Kawabata; Kyoko Hasegawa; Murdorjyn Altankhuu; Ulziiburen Chimedregzen; Luvsanbasaryn Narantuya; Hiromi Hoshino; Kunihiko Hino; Yasuo Kagawa; Hiroaki Okamoto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites.

Authors:  Seung Up Kim; Kwang-Hyub Han; Chung Mo Nam; Jun Yong Park; Do Young Kim; Chae Yoon Chon; Sang Hoon Ahn
Journal:  J Gastroenterol Hepatol       Date:  2008-08-20       Impact factor: 4.029

10.  Epidemiology and outcome of hepatocellular carcinoma in Lombardy.

Authors:  M Borzio; G Colloredo; P Pioltelli; M Quagliuolo
Journal:  Dig Liver Dis       Date:  2007-10-23       Impact factor: 4.088

View more
  6 in total

1.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

2.  Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.

Authors:  Yoona A Kim; Jacqueline Estevez; An Le; Dennis Israelski; Oidov Baatarkhuu; Tserenchimed Sarantuya; Sonom Narantsetseg; Pagbajabyn Nymadawa; Richard H Le; Man-Fung Yuen; Geoffrey Dusheiko; Mario Rizzetto; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2016-11-10

Review 3.  Viral Hepatitis and Liver Diseases in Mongolia.

Authors:  Oidov Baatarkhuu; G Uugantsetseg; D Munkh-Orshikh; N Naranzul; S Badamjav; D Tserendagva; J Amarsanaa; Kim Do Young
Journal:  Euroasian J Hepatogastroenterol       Date:  2017-05-05

4.  Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis.

Authors:  Oidov Baatarkhuu; Hye Won Lee; Jacob George; Dashchirev Munkh-Orshikh; Baasankhuu Enkhtuvshin; Sosorbaram Ariunaa; Mohammed Eslam; Sang Hoon Ahn; Kwang-Hyub Han; Do Young Kim
Journal:  Clin Mol Hepatol       Date:  2017-05-02

5.  Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

Authors:  Marina G Tarakanovskaya; Jigjidsuren Chinburen; Purev Batchuluun; Chogsom Munkhzaya; Genden Purevsuren; Dorjiin Dandii; Tsogkhuu Hulan; Dandii Oyungerel; Galyna A Kutsyna; Alan A Reid; Vika Borisova; Allen I Bain; Vichai Jirathitikal; Aldar S Bourinbaiar
Journal:  J Hepatocell Carcinoma       Date:  2017-04-12

Review 6.  Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia.

Authors:  Oidov Baatarkhuu; Tsagaantsooj Gerelchimeg; Dashchirev Munkh-Orshikh; Badamnachin Batsukh; Ganbold Sarangua; Jazag Amarsanaa
Journal:  Euroasian J Hepatogastroenterol       Date:  2018-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.